Biogetica, has announced its groundbreaking trials result on Herpes, on August 20, 2020. The research successfully marks reduced time & early treatment with the use of combination therapy of the company’s Hyperisince and Reginmune.
It started way back in the year 2004, when Dr T Vijayan from the JSS School of pharmaceuticals discovered that extracts of Hypericum Mysorense, a rare plant from the Nilgiri Hills could completely suppress the herpes virus in-vitro.
Some major pharmaceutical companies decided to synthesise ‘hypericin’ and use it for trials on Herpes & HIV However, the trials were put to a halt by the FDA due to reports of synthetic hypericin molecules having side effects.
Biogetica a global collective of doctors and scientists dedicated to natural medicine was the only firm that actually worked with the plant and not a synthesised version of its active molecule. The challenge was to make it enter cell membranes and work in vivo. There was also attempts to cross the blood brain barrier to get to nerve ganglia where herpes thrives.
Clinical trials published in 2017 showed remarkable results for Herpes, busting the age old myth that Ayurveda takes a longer time to show results and that someone with herpes will always have recurrences. In the trial it was seen that a herpes outbreak usually lasts 21 days without treatment. Acyclovir the FDA approved pharmaceutical for herpes can bring that duration down to nine days. The combination therapy of Hyperisince and Reginmune however brought the average time down to three days. Furthermore 76 per cent of patients with genital herpes who took the combination of Hyperisince and Reginmune did not have a relapse of herpes for the follow up period of two years.